BIOSCIENCE MANAGERS CALLS TIME ON THE NEED FOR INVESTORS TO JOIN GOVERNMENT TO BACK AUSTRALIA’S BIOTECH AND DIGITAL INNOVATORS

1 April 2022: As leading healthcare investors, BioScience Managers welcomes the on-going bipartisan support for Australia’s developing biotechnology sector following the March Federal Budget. However, BioScience Managers is calling for greater backing from Australia’s investment community, particularly institutional investors, to retain the benefits of Australian innovation within Australia as a critical part our post COVID-19 pandemic recovery. […]

Saluda Medical Receives FDA Approval for the Evoke® Spinal Cord Stimulation System to Treat Chronic Intractable Pain

Link to full article Artarmon, Australia – March 8, 2022 – Saluda Medical Pty Limited (“Saluda Medical”), a global medical device company revolutionizing the field of neuromodulation with an emerging portfolio of therapies driven by advanced closed-loop technologies designed to treat debilitating neurological disorders, today announced it received full approval from the United States Food and […]

CalciMedica Announces Publication of Peer-Reviewed Paper in The Journal of Physiology

Link to full article March 10, 2022 Study Supports Development of CRAC Channel Inhibitors for Acute Pancreatitis Study indicates that Orai1 inhibition prevents impaired ductal cell function in acute pancreatitis (AP) Data describes underlying biological mechanisms that may explain key result in a Phase 2a trial of AuxoraTM in patients with AP with systemic inflammatory response […]

Cynata Receives Decision to Grant a Patent in Japan

27 January 2022: Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, has today announced that that a Decision to Grant a Patent has been received from the Japanese Patent Office (JPO) for a patent application covering its proprietary Cymerus™ mesenchymal stem cell technology. The patent application […]

Cynata and FUJIFILM Cellular Dynamics Execute Strategic Manufacturing Agreement

29 December 2021: Cynata Therapeutics Limited (ASX: “CYP” or “Cynata”), a clinical stage biotechnology company specialising in cell therapeutics, is pleased to announce the execution of a Manufacturing Services Agreement (“MSA”) with FUJIFILM Cellular Dynamics, Inc (“FCDI”) for the manufacture and supply of Cynata’s Cymerus™ therapeutic mesenchymal stem cell (“MSC”) products derived from induced pluripotent […]

Cynata Commences DFU Clinical Trial

22 December 2021: Cynata Therapeutics Limited (ASX: “CYP” or “Cynata”), a clinical stage biotechnology company specialising in cell therapeutics, is pleased to announce its clinical trial of CYP-006TK in patients with diabetic foot ulcers (DFU) has commenced and is now open for patient enrolment. The Phase I trial (protocol number CYP-DFU-P1-01) aims to recruit 30 […]

Saluda Medical Announces $125M Equity Financing Led by Redmile Group LLC and New Investors Fidelity Management & Research Company LLC and T. Rowe Price Associates, Inc.

Link to full article March 2, 2022 – Saluda Medical Pty Limited (“Saluda Medical”), a global medical device company revolutionizing the field of neuromodulation with an emerging portfolio of therapies driven by advanced closed-loop technologies designed to treat debilitating neurological disorders, earlier this quarter finalized US $125 million in equity financing, led by existing investor Redmile […]

Saluda Medical Appoints Doug Godshall as Chairman of the Board

Link to full article February 23, 2022 – Saluda Medical Pty Limited (“Saluda Medical”), a global medical device company on a mission to revolutionize the field of neuromodulation with an emerging portfolio of therapies driven by advanced closed-loop technologies designed to treat debilitating neurological disorders, today announced the appointment of Doug Godshall as Chairman of its […]

Publication of Two-Year EVOKE Double-Blind Randomized Controlled Trial Results in JAMA Neurology Demonstrate Sustained Superiority of Evoke® Closed-Loop over Open-Loop Spinal Cord Stimulation

Link to full article Study shows Evoke ECAP-Controlled Closed-Loop Spinal Cord Stimulation provides superior outcomes with no explants due to loss of efficacy and near zero reprogramming burden long term January 10, 2022 – Saluda Medical Pty Limited (“Saluda Medical”), a global company on a mission to revolutionize the field of neuromodulation with an emerging portfolio […]

Fast Company Recognition

Link to full article November 18, 2021 The Next Big Things in Tech We are proud to announce the we have been named as one of Fast Company’s Next Big Things in Tech #FCTechAwards. It’s an honor to be listed among such transformative and groundbreaking organizations.